期刊
VIRUSES-BASEL
卷 4, 期 11, 页码 2711-2735出版社
MDPI
DOI: 10.3390/v4112711
关键词
recombinant adenoviral vector; influenza vaccine; cross-protection; pandemic influenza; H5N1
类别
资金
- National Institutes of Health [1-R43-AI-068285-01, 2-R44-AI-068285-02, 1-UC1-AI-067198-01, N01-AI-30063]
- National Institute of Allergy and Infectious Diseases
The emergence of a highly pathogenic avian influenza virus H5N1 has increased the potential for a new pandemic to occur. This event highlights the necessity for developing a new generation of influenza vaccines to counteract influenza disease. These vaccines must be manufactured for mass immunization of humans in a timely manner. Poultry should be included in this policy, since persistent infected flocks are the major source of avian influenza for human infections. Recombinant adenoviral vectored H5N1 vaccines are an attractive alternative to the currently licensed influenza vaccines. This class of vaccines induces a broadly protective immunity against antigenically distinct H5N1, can be manufactured rapidly, and may allow mass immunization of human and poultry. Recombinant adenoviral vectors derived from both human and non-human adenoviruses are currently being investigated and appear promising both in nonclinical and clinical studies. This review will highlight the current status of various adenoviral vectored H5N1 vaccines and will outline novel approaches for the future.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据